<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352088</url>
  </required_header>
  <id_info>
    <org_study_id>AKTL1</org_study_id>
    <nct_id>NCT04352088</nct_id>
  </id_info>
  <brief_title>Immune Response Features in Allergic Airway Diseases</brief_title>
  <official_title>Investigation of Phenotypes, Endotypes and Immune Response Features in Allergic Airway Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lithuanian University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lithuanian University of Health Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate immune mechanisms and phenotypes and endotypes of allergic
      airway diseases - allergic rhinitis and allergic asthma. Pathogenesis of these diseases are
      not fully investigated yet. Patients with the same disease have different dominant symptoms,
      course of the disease and response to treatment. Moreover, there is a hypothesis about united
      airway disease suggesting that allergic rhinitis and allergic asthma is different
      manifestation of the same disease. This led to assumption of phenotypes and endotypes. This
      classification which still is not unified can let to prescribe personalized treatment for
      every patient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokines level in nasal lavage and peripheral blood after nasal provocation test in different groups.</measure>
    <time_frame>2 hours</time_frame>
    <description>Cytokines (IL-13, IL-10, IL-22, etc.) level will be measured by ELISA before and after nasal provocation test with house dust mites.
Comparison between different groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokines level in nasal lavage and peripheral blood after nasal provocation test in different groups.</measure>
    <time_frame>22 hours</time_frame>
    <description>Cytokines (IL-13, IL-10, IL-22, etc.) level will be measured by ELISA before and after nasal provocation test with house dust mites.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>Allergic rhinitis patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergic rhinitis and asthma patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy individuals</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nasal provocation test</intervention_name>
    <description>Allergen extract under controlled conditions will be applied into nasal mucous.</description>
    <arm_group_label>Allergic rhinitis and asthma patients</arm_group_label>
    <arm_group_label>Allergic rhinitis patients</arm_group_label>
    <arm_group_label>Healthy individuals</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with allergic rhinitis with or without asthma and healthy individuals for
        control group.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypersensitivity to house dust mites

          -  Allergic rhinitis with or without mild to moderate asthma

        Exclusion Criteria:

          -  Acute or chronic infections

          -  Use of systemic immunosupresants (wait 1 month)

          -  Use of systemic or local antihistamines (wait 1 week)

          -  Use of intranasal steroids (wait 1 month)

          -  Oncological or active autoimmune diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Tamasauskiene, MD</last_name>
    <phone>+37061569127</phone>
    <email>lau.tamasauskiene@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brigita Sitkauskiene</last_name>
    <email>brigita.sitkauskiene@kaunoklinikos.lt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kauno klinikos</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Lapinskas, PhD</last_name>
      <email>tomas.lapinskas@kaunoklinikos.lt</email>
    </contact>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lithuanian University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Brigita Sitkauskiene</investigator_full_name>
    <investigator_title>Prof., Head of Department of Immunology and Allergology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

